MSC Exosomes for Sjögren’s Syndrome
Mesenchymal stem cell (MSC)-derived exosomes are studied in regenerative research for Sjögren’s syndrome and related autoimmune dryness. This overview is provided for research and educational purposes only.
What MSC exosomes are
MSC-derived exosomes are nanoscale, cell-free extracellular vesicles (roughly 30–150 nm) that carry signaling cargo such as proteins, lipids, and microRNA. They are not stem cells, and BioRegenEx supplies them as characterized, research-use-only material with per-lot documentation.
What the research explores
In preclinical Sjögren’s models, MSC-derived exosomes have been studied for immunomodulatory signaling — for example influencing B-cell and T-follicular-helper responses and salivary-gland inflammation (via microRNA cargo). These are research findings only. The studies are indexed in our Exosome Research Library under Immunology.
Why sourcing and characterization matter
Because exosome composition depends on the source cells and manufacturing, research-grade material is defined by measurement — particle size and concentration, sterility and endotoxin screening, and a per-lot Certificate of Analysis.
Frequently Asked Questions
Are MSC exosomes an approved Sjögren’s treatment?
No. MSC-derived exosomes are not FDA-approved to treat this or any condition and are supplied for research use only (RUO).
What does the research focus on?
Preclinical research focuses on immunomodulatory signaling and inflammation.
For research and educational purposes; research-use-only.
These statements have not been evaluated by the FDA. BioRegenEx supplies MSC-derived exosomes for research use only (RUO); they are not intended to diagnose, treat, cure, or prevent any disease. This content is educational and is not medical advice.